---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-302302"
form_type: "8-K"
ticker: "COGT"
cik: "0001622229"
company_name: "Cogent Biosciences, Inc."
filed_at: "2022-12-12T23:59:59+00:00"
generated_at: "2026-06-21T06:10:36.387472+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Cogent Biosciences reports 89% ORR in TKI-naive AdvSM patients from Phase 2 APEX trial

## Summary
- 89% ORR in TKI-naïve patients; 73% ORR in all evaluable patients (median 27-week follow-up).
- First confirmed CR at 20 weeks; 77% with ≥2 cycles had complete clearance of bone marrow mast cell aggregates.
- No related cognitive effects or intracranial bleeding; favorable safety profile with mostly Grade 1/2 events.
- Median age 69 years; subtypes: ASM (3), SM-AHN (12), MCL (1); 3 had prior avapritinib/midostaurin.
- Plans to present initial PEAK lead-in data H1 2023 and SUMMIT data H2 2023.

## SEC filing metadata
- accession: 0001193125-22-302302
- form_type: 8-K
- ticker: COGT
- cik: 0001622229
- company_name: Cogent Biosciences, Inc.
- filed_at: 2022-12-12T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1622229/000119312522302302/0001193125-22-302302-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1622229/000119312522302302/d421322d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-302302
- JSON: https://secwatch.observer/filing/0001193125-22-302302.json
- Plain text: https://secwatch.observer/filing/0001193125-22-302302.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.